UK Axes Financial support for AMR Fleming Fund
21 July 2025
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
UK Axes Financial support for AMR Fleming Fund
UK Decision to Cancel Fleming Fund Increases Urgency for Innovative Antimicrobial Solutions; Ondine Biomedical Poised to Lead Fight Against Superbugs
Ondine Biomedical Inc. (AIM: OBI). The UK government's decision to cancel the Fleming Fund - a cornerstone initiative in the global fight against antimicrobial resistance (AMR) - comes at a time when new projections point to an escalating global crisis, threatening millions of lives and the world economy. With models now suggesting drug-resistant infections will cost nearly $2 trillion annually by 2050, Ondine Biomedical's advanced photodisinfection platform stands ready to address the widening gap in infection control and treatment.
The Fleming Fund had played a crucial role in supporting AMR surveillance and stewardship in low - and middle - Income countries, delivering early warnings and enabling coordinated responses. Its cancellation, leaves a dangerous void in the global health security net, as both The Guardian and leading experts warn of millions more deaths if resistant infections continue to rise unchecked.
The Cost of Inaction
Recent research by the Center for Global Development reveals the true consequences of AMR: drug-resistant infections already cost twice as much to treat as non-resistant infections. Without robust alternatives, the world faces annual GDP losses of $1.7 trillion by 2050 - devastating healthcare systems in the UK, US, and Europe most acutely.
How Ondine Biomedical's Solutions Fill the Gap
Ondine Biomedical has a platform of economical light-based technologies - including its Steriwave™ platform - that offers an urgently needed response to the threat of multidrug resistant infections. Unlike conventional antibiotics, Ondine's photodisinfection uses visible red light combined with a photosensitizer to target and destroy all bacteria, fungi and viruses - including highly resistant "superbugs" - in minutes, without contributing to antimicrobial resistance.
"Ondine's medical devices are engineered to prevent and treat infections in environments where antibiotics are failing," said Carolyn Cross, CEO of Ondine Biomedical. "As stewardship initiatives lose funding, our technologies provide a scalable, rapid solution that reduces healthcare costs, improves outcomes, and protects society against the rising tide of drug-resistant diseases."
Proven Impact: Saving Lives and Costs
Clinical studies show that implementing Ondine's photodisinfection technology in surgical and ICU settings can reduce hospital-acquired infections, translating into thousands of lives saved and millions in cost avoidance. Hospitals adopting Ondine's platform report lower readmission rates, shorter hospital stays, and a dramatic reduction in the need for expensive last-resort antibiotics.
A Call for Investment in Proven Technologies
With the withdrawal of Fleming Fund resources and persistent aid cuts globally, the need for immediate, innovative interventions is clear. Policymakers, health systems, and philanthropists must urgently invest in non-antibiotic infection control to safeguard healthcare infrastructure, national security, and the world economy.
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
Strand Hanson Limited (Nominated & Joint Financial Adviser) |
|
|
James Harris, Richard Johnson |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt (Broker & Joint Financial Adviser) |
|
|
James Steel, Dr. Chris Golden |
+44 (0)20 7418 8900 |
|
|
|
|
Vane Percy & Roberts (Media Contact) |
|
|
Simon Vane Percy |
+44 (0)77 1000 5910 |
References:
· The Guardian: "Superbugs could kill millions more and cost $2tn a year by 2050, models show" (20 July 2025)
· Center for Global Development: [Forecasting the Fallout: The Economic Impacts of Antimicrobial Resistance in Humans]
· The Times: "UK fund to fight antibiotic resistance axed in astonishing cut" (17 July 2025)
About Ondine Biomedical Inc.
Ondine Biomedical Inc., a Canadian life sciences company and CAN Health Network member, is a leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and has regulatory approval in Canada, Australia, Mexico, and several other countries under the name Steriwave®. In the US, Ondine's nasal photodisinfection therapy has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, chronic wounds, and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund